CA2598893C - Eml4-alk fusion gene - Google Patents

Eml4-alk fusion gene Download PDF

Info

Publication number
CA2598893C
CA2598893C CA 2598893 CA2598893A CA2598893C CA 2598893 C CA2598893 C CA 2598893C CA 2598893 CA2598893 CA 2598893 CA 2598893 A CA2598893 A CA 2598893A CA 2598893 C CA2598893 C CA 2598893C
Authority
CA
Canada
Prior art keywords
eml4
seq
polypeptide
polynucleotide
alk
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA 2598893
Other languages
English (en)
French (fr)
Other versions
CA2598893A1 (en
Inventor
Hiroyuki Mano
Sadao Kuromitsu
Nobuaki Shindo
Takatoshi Soga
Takashi Furutani
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astellas Pharma Inc
CureGene KK
Original Assignee
Astellas Pharma Inc
CureGene KK
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc, CureGene KK filed Critical Astellas Pharma Inc
Priority to AT07254044T priority Critical patent/ATE450547T1/de
Priority to EP20070254044 priority patent/EP1914240B1/en
Priority to JP2007265917A priority patent/JP4303303B2/ja
Priority to DE200760003543 priority patent/DE602007003543D1/de
Priority to EP20090006058 priority patent/EP2116553B1/en
Priority to ES07254044T priority patent/ES2335368T3/es
Priority to ES09006058.3T priority patent/ES2515170T3/es
Publication of CA2598893A1 publication Critical patent/CA2598893A1/en
Priority to JP2009035918A priority patent/JP5172736B2/ja
Application granted granted Critical
Publication of CA2598893C publication Critical patent/CA2598893C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CA 2598893 2006-10-11 2007-08-24 Eml4-alk fusion gene Active CA2598893C (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
EP20070254044 EP1914240B1 (en) 2006-10-11 2007-10-11 EML4-ALK fusion gene
JP2007265917A JP4303303B2 (ja) 2006-10-11 2007-10-11 Ｅｍｌ４−ａｌｋ融合遺伝子
DE200760003543 DE602007003543D1 (de) 2006-10-11 2007-10-11 EML4-ALK-Fusionsgen
EP20090006058 EP2116553B1 (en) 2006-10-11 2007-10-11 EML4-ALK fusion gene
AT07254044T ATE450547T1 (de) 2006-10-11 2007-10-11 Eml4-alk-fusionsgen
ES07254044T ES2335368T3 (es) 2006-10-11 2007-10-11 Gen de fusion eml4-alk.
ES09006058.3T ES2515170T3 (es) 2006-10-11 2007-10-11 Gen de fusión EML4-ALK
JP2009035918A JP5172736B2 (ja) 2006-10-11 2009-02-18 Ｅｍｌ４−ａｌｋ融合遺伝子

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP277718/2006 2006-10-11
JP2006277718 2006-10-11
JP2007120670 2007-05-01
JP120670/2007 2007-05-01

Publications (2)

Publication Number Publication Date
CA2598893A1 CA2598893A1 (en) 2008-04-11
CA2598893C true CA2598893C (en) 2012-04-10

Family

ID=39277176

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2598893 Active CA2598893C (en) 2006-10-11 2007-08-24 Eml4-alk fusion gene

Country Status (7)

Country Link
US (7) US7728120B2 (enExample)
EP (1) EP2116553B1 (enExample)
JP (2) JP4303303B2 (enExample)
AT (1) ATE450547T1 (enExample)
CA (1) CA2598893C (enExample)
DE (1) DE602007003543D1 (enExample)
ES (2) ES2515170T3 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9012462B2 (en) 2008-05-21 2015-04-21 Ariad Pharmaceuticals, Inc. Phosphorous derivatives as kinase inhibitors

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120208824A1 (en) 2006-01-20 2012-08-16 Cell Signaling Technology, Inc. ROS Kinase in Lung Cancer
US8168383B2 (en) 2006-04-14 2012-05-01 Cell Signaling Technology, Inc. Gene defects and mutant ALK kinase in human solid tumors
PL2450437T3 (pl) 2006-04-14 2017-12-29 Cell Signaling Technology Inc Defekty genu i zmutowana kinaza ALK w ludzkich guzach litych
WO2008127248A1 (en) * 2007-04-13 2008-10-23 Cell Signaling Technology, Inc. Gene defects and mutant alk kinase in human solid tumors
CA2598893C (en) * 2006-10-11 2012-04-10 Astellas Pharma Inc. Eml4-alk fusion gene
TWI389893B (zh) * 2007-07-06 2013-03-21 Astellas Pharma Inc 二（芳胺基）芳基化合物
AU2009215168A1 (en) * 2008-02-12 2009-08-20 Dana-Farber Cancer Institute Fish assay for EML4 and ALK fusion in lung cancer
JP2009219728A (ja) * 2008-03-18 2009-10-01 Daito Giken:Kk 遊技台
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
CA2762108A1 (en) * 2009-05-15 2010-11-18 Insight Genetics, Inc. Methods and compositions relating to fusions of alk for diagnosing and treating cancer
US20120202214A1 (en) * 2009-10-06 2012-08-09 Kazuya Omi Method for detecting fusion gene
US9175350B2 (en) 2009-12-22 2015-11-03 Quest Diagnostics Investments Incorporated EML4-ALK translocations in lung cancer
JP5861629B2 (ja) * 2010-02-22 2016-02-16 富士レビオ株式会社 癌遺伝子の同定方法、癌遺伝子発現細胞の樹立方法、および癌遺伝子標的薬のスクリーニング方法
US8383793B2 (en) 2010-04-15 2013-02-26 St. Jude Children's Research Hospital Methods and compositions for the diagnosis and treatment of cancer resistant to anaplastic lymphoma kinase (ALK) kinase inhibitors
WO2011130635A2 (en) * 2010-04-16 2011-10-20 Response Genetics, Inc. Primers, probes, methods and kits for the detection of eml4-alk variants
US20120101108A1 (en) 2010-08-06 2012-04-26 Cell Signaling Technology, Inc. Anaplastic Lymphoma Kinase In Kidney Cancer
EP2606886B1 (en) 2010-08-20 2020-01-08 Chugai Seiyaku Kabushiki Kaisha Composition comprising tetracyclic compound
WO2012029577A1 (ja) * 2010-09-02 2012-03-08 学校法人 久留米大学 単分子dnaから形成される環状dnaの作成方法
JP2014005206A (ja) * 2010-10-22 2014-01-16 Astellas Pharma Inc アリールアミノヘテロ環カルボキサミド化合物
JP5769952B2 (ja) * 2010-11-12 2015-08-26 株式会社Ｌｓｉメディエンス Ｅｍｌ４−ａｌｋ融合遺伝子の高感度検出方法
WO2012075318A2 (en) * 2010-12-01 2012-06-07 Cell Signaling Technology, Inc. Fn1 and alk gene translocations in cancer and alk kinase expression in ovarian cancer
PT2670401E (pt) * 2011-02-02 2015-10-12 Novartis Ag Métodos de utilização de inibidores de alk
WO2012139134A2 (en) * 2011-04-07 2012-10-11 Coferon, Inc. Methods of modulating oncogenic fusion proteins
AU2012250517B2 (en) 2011-05-04 2016-05-19 Takeda Pharmaceutical Company Limited Compounds for inhibiting cell proliferation in EGFR-driven cancers
CN103890175B (zh) * 2011-08-31 2015-12-09 学校法人久留米大学 在dna分子的环化中仅选择由单分子形成的环化dna的方法
WO2013158859A1 (en) 2012-04-18 2013-10-24 Cell Signaling Technology, Inc. Egfr and ros1 in cancer
JP6469567B2 (ja) 2012-05-05 2019-02-13 アリアド・ファーマシューティカルズ・インコーポレイテッド Ｅｇｆｒ発動性がんの細胞増殖阻害用化合物
US9084456B1 (en) * 2012-05-28 2015-07-21 Jack Zemer Linkage for jewelry components
EP2892536B1 (en) 2012-09-06 2019-12-18 Epizyme, Inc. Method of treating leukemia
JP2016510316A (ja) * 2012-12-21 2016-04-07 エピザイム，インコーポレイティド 白血病の治療に使用するためのｄｏｔ１ｌ阻害剤
WO2014128235A1 (en) 2013-02-22 2014-08-28 F. Hoffmann-La Roche Ag Methods of treating cancer and preventing drug resistance
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
US10705087B2 (en) 2013-07-26 2020-07-07 Japanese Foundation For Cancer Research Detection method for NTRK3 fusion
JP6806440B2 (ja) * 2013-10-29 2021-01-06 公益財団法人がん研究会 新規融合体及びその検出法
JPWO2015064621A1 (ja) * 2013-10-29 2017-03-09 公益財団法人がん研究会 新規融合体及びその検出法
WO2015111716A1 (ja) 2014-01-24 2015-07-30 公益財団法人がん研究会 新規融合体及びその検出法
RU2016146119A (ru) 2014-04-25 2018-05-29 Чугаи Сейяку Кабусики Кайся Новый кристалл тетрациклического соединения
WO2015163448A1 (ja) 2014-04-25 2015-10-29 中外製薬株式会社 ４環性化合物を高用量含有する製剤
TWI718102B (zh) 2014-08-08 2021-02-11 日商中外製藥股份有限公司 ４環性化合物的非晶質體
EP2990493B1 (en) 2014-09-01 2017-05-24 ARKRAY, Inc. Primer reagent for amplifying alk fusion gene, alk fusion gene amplification reagent kit including the same, and alk fusion gene amplification method and alk fusion gene analysis method using the same
WO2017122816A1 (ja) 2016-01-15 2017-07-20 公益財団法人がん研究会 新規融合体及びその検出法
JP6740172B2 (ja) * 2017-05-02 2020-08-12 セル・シグナリング・テクノロジー・インコーポレイテツド ヒト固形腫瘍における遺伝子欠失及び突然変異ａｌｋキナーゼ
US12473548B2 (en) * 2018-06-27 2025-11-18 City Of Hope Modification of small RNAs for therapeutic uses
BR112020025499A2 (pt) 2018-06-29 2021-03-09 Chugai Seiyaku Kabushiki Kaisha Composição farmacêutica que compreende agente básico pouco solúvel
JP7385191B2 (ja) * 2019-08-30 2023-11-22 学校法人同志社 Ｅｍｌ４－ａｌｋ阻害ペプチドおよびこれを含む肺がん治療薬
JP2020156481A (ja) * 2020-04-06 2020-10-01 セル・シグナリング・テクノロジー・インコーポレイテツド ヒト固形腫瘍における遺伝子欠失及び突然変異ａｌｋキナーゼ
WO2023074785A1 (ja) 2021-10-28 2023-05-04 中外製薬株式会社 シロップ剤
CN119451699A (zh) 2022-07-04 2025-02-14 中外制药株式会社 并用药物
TW202425998A (zh) 2022-08-30 2024-07-01 日商中外製藥股份有限公司 併用醫藥

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2338210T3 (es) 1999-11-11 2010-05-05 Astellas Pharma Inc. Metaloproteasa novedosa que tiene actividad agrecanasa.
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
US7872014B2 (en) 2003-07-23 2011-01-18 Exelixis, Inc. Anaplastic lymphoma kinase modulators and methods of use
ATE542801T1 (de) 2003-08-15 2012-02-15 Novartis Ag Zur behandlung von neoplastischen krankheiten, entzündlichen erkrankungen und erkrankungen des immunsystems geeignete 2,4-pyrimidindiamine
CA2559866A1 (en) 2004-03-31 2005-10-20 Exelixis, Inc. Anaplastic lymphoma kinase modulators and methods of use
WO2008127248A1 (en) 2007-04-13 2008-10-23 Cell Signaling Technology, Inc. Gene defects and mutant alk kinase in human solid tumors
CA2598893C (en) 2006-10-11 2012-04-10 Astellas Pharma Inc. Eml4-alk fusion gene
TWI389893B (zh) 2007-07-06 2013-03-21 Astellas Pharma Inc 二（芳胺基）芳基化合物

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9012462B2 (en) 2008-05-21 2015-04-21 Ariad Pharmaceuticals, Inc. Phosphorous derivatives as kinase inhibitors

Also Published As

Publication number Publication date
US20150184161A1 (en) 2015-07-02
JP2008295444A (ja) 2008-12-11
ES2515170T3 (es) 2014-10-29
US20080090776A1 (en) 2008-04-17
US20180066266A1 (en) 2018-03-08
DE602007003543D1 (de) 2010-01-14
JP2009100783A (ja) 2009-05-14
US9932589B2 (en) 2018-04-03
US7728120B2 (en) 2010-06-01
US20100240673A1 (en) 2010-09-23
US8197818B2 (en) 2012-06-12
US20110230545A1 (en) 2011-09-22
EP2116553A1 (en) 2009-11-11
US7964710B2 (en) 2011-06-21
JP4303303B2 (ja) 2009-07-29
US9029521B2 (en) 2015-05-12
US7605131B2 (en) 2009-10-20
ES2335368T3 (es) 2010-03-25
CA2598893A1 (en) 2008-04-11
EP2116553B1 (en) 2014-07-30
US20130158095A1 (en) 2013-06-20
ATE450547T1 (de) 2009-12-15
JP5172736B2 (ja) 2013-03-27
US20090099193A1 (en) 2009-04-16

Similar Documents

Publication Publication Date Title
US9029521B2 (en) EML4-ALK fusion gene
EP1914240B1 (en) EML4-ALK fusion gene
AU2020202555B2 (en) Novel fusion molecules and uses thereof
US20240094208A1 (en) MEK1 Mutation Conferring Resistance to RAF and MEK Inhibitors
KR102106962B1 (ko) 신규 fgfr3 융합체
JP2009278982A (ja) 真性赤血球増加症に関与するｊａｋ２の変異の識別方法
WO2015066452A2 (en) Methods of treating pediatric cancers
JPWO2012014795A1 (ja) 新規ｒｅｔ融合体の検出法
MX2012009784A (es) Mutaciones del protooncogen de serina/treonina-proteina cinasa b-raf (braf) que confieren resistencia a los inhibidores del protooncogen de serina/treonina-proteina cinasa b-raf.
KR102406334B1 (ko) Nras-돌연변이 암의 치료에서 사용하기 위한 egfr 억제제 및 mek 억제제의 조합물
JPWO2007026969A1 (ja) 創薬標的タンパク質及び標的遺伝子、並びにスクリーニング方法
WO2012096325A1 (ja) 新規ｂｒａｆ融合体の検出法
JPWO2015064620A1 (ja) 新規融合体及びその検出法

Legal Events

Date Code Title Description
EEER Examination request
MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 17TH ANNIV.) - STANDARD

Year of fee payment: 17

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 18TH ANNIV.) - STANDARD

Year of fee payment: 18

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250702

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250702

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 19TH ANNIV.) - STANDARD

Year of fee payment: 19

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260702

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260702